The Study Of Changes And Clinical Significance Of The Thromboxane B₂and6-keto-prostaglandin F1Alpha In Low-dose Heparin Therapy For Septic Patients

Object To Explore the dynamic changes and clinical significance of6-keto-prostaglandinF_1α(6-keto-PGF_1α) and thromboxane B₂in low-dose heparin therapy for septic patients.Method In this issue,we would adopt randomized controlled trials.75septic patients with meetinginclusion criteria were randomly divided into three groups: Control group,Anticoagulation controlgroup of Low-dose heparin（UFH group5u/（kg.h） continuous intravenous infusion of1week）, Anti-coagulation control group of low molecular weight heparin（LMWH group the enoxaparin sodium100U/kg, Once-daily,subcutaneous injection one week）. We would respectively determinate thelevels of TXB₂,6-keto-PGF_1α and CD62p, platelet（PLT）, prothrombin time （PT）, activated partialthromboplastin time（APTT）,fibrinogen, D-dimer （D-dimer）and observing Score of acute physiologyand chronic health evaluation II （APACHE II）and record28days （d） mortality in1d,4d,7d, and10d in all septic patients with be hospitalized and after of be hospitalized.At the same time,Selecting25healthy people for physical examination as nomal contrast group.Result The expression levels of TXB₂,6-keto-PGF_1α and CD62p were much more in contrast groupcompared with nomal contrast group, and the difference was statistically significant （P<0.05）. TheCD62p,6-keto-PGF_1α and thromboxane B₂levels and APACHE II in anticoagulation groupdecreased with passage of time. To TXB₂and CD62p the differences were significant between theresults on the day7,10and that of the first and fourth day （all P<0.008）. To CD62Pthe differenceswere significant between the results on the day10and that of the first day （P<0.008）,and thedifferences were significant between the results on the day7,10and that of the fourth day （bothP<0.008）;To APACHEâ…¡the differences were significant between the results on the day10and thatof the first day （P<0.008）. The three indicators of the control group slightly decreased first and thenincreased. The anticoagulation group with the control group compared to the TXB₂and CD62psignificant difference in the day of7and10（all P <0.008）.28d fatality rate of the group of UFHand the group of LMWH were24%（6/25）and24%（6/25）, compared with the control group was32%（8/25）to reduce, but the difference was not statistically significant （P>0.05）. The differencePT,APTT,FIB,PLT and D-D was not significant between the two treatment groups. Through thecorrelation of CD62p and TXB₂with APACHEâ…¡score was analyzed in anticoagulation group, thepositive correlations were found （r=0.837and0.674,both P<0.05）.Conclusion Early application of low-dose heparin continuous infusion in the treatment of sepsissignificantly inhibited TXB₂and CD62p expression, reduced the ratio of T/K,stimulated thegeneration of6-keto-PGF_1α, taken advantage of balance organism anticoagulant/procoagulant,andmay reduce mortality and clinical application security; TXB₂/6-keto-PGF_1α and CD62p moresensitive reflecting Cruor disorders than conventional coagulation indicators.